International

Where are you?

To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.

image/svg+xml

Media & Investors

Transparency is important to us. Find important information about Kuros Biosciences here – from our corporate documents to our current share price.

Press releases

Here are our latest press releases.
For archived news items, please go to our Resources center. To subscribe to receive our press releases, please click here.

24 Apr 2024

Adhoc Press Release

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOs sales

17 Apr 2024

Annual General Meeting of Kuros Biosciences approves all resolutions

13 Mar 2024

Adhoc Press Release

Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

08 Mar 2024

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

01 Feb 2024

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

31 Jan 2024

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Investor calendar

Date Event
Aug 08, 2024

Trading Update H1 2024

Oct 10, 2024

Trading Update Q3 2024

Reports, Corporate Governance & Meetings

Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.

Reports & Presentations

Corporate Governance

Shareholder Meetings

Regulatory filings

Information on disclosures under the Swiss Stock Exchange Act can be found on the website of the SIX Swiss Exchange website.

Management Transactions

Outstanding Options

Significant Shareholder Transactions

Stabilization

Analysts

For more information regarding analyst reports, please contact:

Laura Pfeifer-Rossi
Octavian AG
sales@octavian.ch
Tel: +41 44 520 1588

Want to receive our press releases?